Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | BAD | Q92934 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24428893 | 0.95 | CES1 (0.39) | CES1BCL2L1BADNOS3NOS1 | |
| SCHEMBL28759083 | 0.87 | KIF11 (0.34) | CES1TSHRKIF11ALDH1A1 | |
| SCHEMBL20112700 | 0.80 | CES1 (0.52) | CES1BCL2L1BADNOS3NOS1 | |
| SCHEMBL19995834 | 0.79 | NOS3 (0.44) | CES1BCL2L1BADNOS3NOS1 | |
| SCHEMBL16646844 | 0.79 | BCL2L1 (0.52) | CES1BCL2L1BADNOS3NOS1 | |
| SCHEMBL24884716 | 0.79 | CES1 (0.40) | CES1BCL2L1BADNOS3NOS1 | |
| SCHEMBL19596727 | 0.79 | CES1 (0.40) | CES1BCL2L1BADNOS3NOS1 | |
| SCHEMBL3777343 | 0.79 | PNMT (0.43) | CES1BCL2L1BADNOS3NOS1 | |
| SCHEMBL1278375 | 0.78 | BCL2L1 (0.52) | CES1BCL2L1BADNOS3NOS1 | |
| SCHEMBL15502922 | 0.78 | HTR2C (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| US-7105527-B2 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2006-09-12 | — | — | US | disclosed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | disclosed |
| US-6908924-B2 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | PHARMASSET, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | CES1 340/4885BCL2L1 3490/4885BAD 845/4885 |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | CES1 310/4885BCL2L1 3793/4885BAD 795/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | CES1 78/4885BCL2L1 2871/4885BAD 575/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | CES1 227/4885BCL2L1 3469/4885BAD 706/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | CES1 851/4885BCL2L1 4397/4885BAD 1821/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | CES1 333/4885BCL2L1 3568/4885BAD 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.